1st Quarter - Report

ABBVIE, INC. for ABBVIE INC.

Firm
Client
Income
—
Expenses
$2,460,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

S. 41: Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 242: Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal Part D policy issues including non-interference and rebates policy issues Drug cost and pricing policy issues Center for Medicare and Medicaid Innovation (CMMI) transparency and other policy issues

LobbyistCovered position, as disclosed
DANIEL BACHNER —
JOHN P. FORD —
STEPHEN SCANGO —
HEATHER STRAWN —

Contacted: Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); SENATE; Health Resources & Services Administration (HRSA); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO)

Bills named: S. 251 (115th), S. 260 (115th), H.R. 849 (115th), S. 41 (115th), H.R. 242 (115th), H.J.Res. 51 (115th), S.J.Res. 16 (115th)

Trade (domestic/foreign) TRD

U.S. Trade policy, including IP and pharmaceutical market access issues Japan Pricing and Regulatory Issues U.S. IP policy at multilateral organizations Philippine Potential Compulsory Licensing Issue

LobbyistCovered position, as disclosed
HEATHER STRAWN —

Contacted: Commerce, Dept of (DOC); Patent & Trademark Office (PTO); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); State, Dept of (DOS); SENATE

Taxation/Internal Revenue Code TAX

Senate and House Committee Tax Reform Proposals Puerto Rican Economy and Debt Relief Proposals Proposals to reform domestic and international tax structures

LobbyistCovered position, as disclosed
DANIEL BACHNER —
JOHN P. FORD —
STEPHEN SCANGO —
HEATHER STRAWN —

Contacted: Patent & Trademark Office (PTO); State, Dept of (DOS); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; SENATE; Health Resources & Services Administration (HRSA)

Budget/Appropriations BUD

S.Con.Res 3: Budget Resolution - Provisions related to the biopharmaceutical industry including importation and non-interference

LobbyistCovered position, as disclosed
DANIEL BACHNER —
JOHN P. FORD —
STEPHEN SCANGO —
HEATHER STRAWN —

Contacted: State, Dept of (DOS); Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; Commerce, Dept of (DOC); Health Resources & Services Administration (HRSA); Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: S.Con.Res. 3 (115th)

Copyright/Patent/Trademark CPT

S. 124: Preserve Access to Affordable Generics Act - Provisions related to patent settlements Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues

LobbyistCovered position, as disclosed
DANIEL BACHNER —
STEPHEN SCANGO —
HEATHER STRAWN —

Contacted: Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Medicare Payment Advisory Commission (MedPAC); State, Dept of (DOS); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); SENATE; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Bills named: S. 124 (115th)

Health Issues HCR

S. 64: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation S. 92: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation S. 204: Trickett Wendler Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness S. 456: RACE for Children Act - Provisions related to pediatric studies S. 469: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 771: Improving Access to Affordable Prescription Drugs Act - Provisions related to drug pricing H.R. 749: Lower Drug Costs Through Competition Act - Provisions related to generic drug approvals and priority review vouchers H.R. 820: Childhood Cancer STAR Act - Provisions related to expanded access and other policy issues H.R. 878: Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness H.R. 1231: RACE for Children Act - Provisions related to pediatric studies H.R. 1245: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 1480: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation H.R. 1628: American Health Care Act of 2017 - Provisions related to the biopharmaceutical industry including repeal of brand pharmaceutical manufacturer fee and individual and employer mandates, insurance affordability provisions, and Medicaid reforms H.R. 1776: Improving Access to Affordable Prescription Drugs Act - Provisions related to drug pricing Prescription Drug User Fee Act (PDUFA) reauthorization Biologics User Fee Act (BsUFA) reauthorization 340B drug discount program policy issues Orphan Drug Act policy issues Biologics Price Competition and Innovation Act (BPCIA) implementation issues Patient assistance program policy issues

LobbyistCovered position, as disclosed
DANIEL BACHNER —
JOHN P. FORD —
STEPHEN SCANGO —
HEATHER STRAWN —

Contacted: Patent & Trademark Office (PTO); State, Dept of (DOS); SENATE; Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR)

Bills named: S. 92 (115th), S. 469 (115th), H.R. 1480 (115th), H.R. 1231 (115th), S. 771 (115th), H.R. 878 (115th), H.R. 1245 (115th), S. 456 (115th), H.R. 1628 (115th), H.R. 820 (115th), S. 64 (115th), S. 204 (115th), H.R. 749 (115th), H.R. 1776 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.